Single daily dose amikacin in paediatric patients with severe Gram-negative infections

H. Trujillo, J. Robledo, C. Robledo, D. Espinal, G. Garces, M. Jorje, C. Restrepo, F. Restrepo, G. I.M. De Rodriguez, M. C.T. De Guitierrez

Research output: Contribution to journalArticle in an indexed scientific journalpeer-review

20 Scopus citations


Twenty-five children with serious Gram-negative infections were treated in a prospective study with amikacin 20 mg/kg administered in a single daily dose as a 30 min iv infusion for 4 to 12 days. In nine cases the amikacin was combined with β-lactam antibiotics. Escherichia coli were the most frequent bacteria isolated followed by K pneumoniae, Providencia and Enterobacter spp. and Pseudomonas aeruginosa with MICs ranging from 1 to 16 mg/l. Mean (±S.D.) peak and trough concentrations of days 1 and 4 of therapy ranged from 49 ± 13.5 to 53.6 ± 13.4 mg/l and 6 ± 1.4 to 7.7 ±4.1 mg/l respectively. All patients were clinically and bacteriologically cured. No significant adverse reactions were observed. The results suggest that administration of a single daily dose of 20 mg/kg amikacin should be considered practical and safe in children. Further studies are needed.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Issue numberSUPPL. C
StatePublished - 1991
Externally publishedYes


Dive into the research topics of 'Single daily dose amikacin in paediatric patients with severe Gram-negative infections'. Together they form a unique fingerprint.

Cite this